|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received February 5, 2004
Revised March 11, 2004
Accepted after revision May 17, 2004
1 University Laboratory of Physiology, University of Oxford, Parks Road, Oxford OX1 3PT
2 Department of Cardiovascular Medicine, University of Oxford
* To whom correspondence should be addressed. E-mail: david.paterson{at}physiol.ox.ac.uk.
We tested the hypothesis that a single allele deletion of neuronal nitric oxide synthase (nNOS) would impair the neural control of heart rate following physical training, and that this phenotype could be restored following targeted gene transfer of nNOS. Voluntary wheel-running (+EX) in heterozygous nNOS knockout mice (nNOS+/-,+EX; n=52; peak performance 9.1±1.8 km/day) was undertaken and compared to wild-type mice (n=38; 9.5±0.8 km/day). In anaesthetised wild-type mice, exercise-training increased phenylephrine-induced bradycardia by 67%(measured as heart rate change in beats per minute by the change in arterial blood pressure in mmHg) or pulse interval response to phenylephrine by 52% (measured as inter-beat interval in milliseconds by the change in blood pressure). Heart rate changes or inter-beat interval changes to right vagal nerve stimulation were also enhanced by exercise-training in wild-type atria (P<0.05); whereas both in-vivo and in-vitro responses to exercise were absent in nNOS+/- mice. nNOS inhibition attenuated heart rate responses to vagal nerve stimulation in all atria (P<0.05) and normalised the responses in wild-type, +EX with respect to wild-type with no exercise (-EX) atria. Atrial nNOS mRNA and protein were increased in wild-type, +EX compared to wild-type,-EX (P<0.05); although exercise failed to have any effect in nNOS+/- atria. In-vivo nNOS gene transfer using adenoviruses targeted to atrial ganglia enhanced choline acetyltransferase/nNOS colocalization (P<0.05) and increased phenylephrine-induced bradycardia in-vivo and heart rate responses to vagal nerve stimulation in-vitro compared to gene transfer of enhanced green fluorescent protein (eGFP, P<0.01). This difference was abolished by nNOS inhibition (P<0.05). In conclusion, genomic regulation of NO-bioavailability from nNOS in cardiac autonomic ganglia in response to training is dependent on both alleles of the gene. Although basal expression of nNOS is normal, polymorphisms of nNOS may interfere with neural regulation of heart rate following training. Targeted gene transfer of nNOS can restore this impairment.
This article has been cited by other articles:
![]() |
J. Davis, M. V. Westfall, D. Townsend, M. Blankinship, T. J. Herron, G. Guerrero-Serna, W. Wang, E. Devaney, and J. M. Metzger Designing Heart Performance by Gene Transfer Physiol Rev, October 1, 2008; 88(4): 1567 - 1651. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Dawson, D. Li, T. Woodward, Z. Barber, L. Wang, and D. J. Paterson Cardiac cholinergic NO-cGMP signaling following acute myocardial infarction and nNOS gene transfer Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H990 - H998. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Stewart, M. S. Medow, C. T. Minson, and I. Taneja Cutaneous neuronal nitric oxide is specifically decreased in postural tachycardia syndrome Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2161 - H2167. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Heaton, D. Li, S. C. Almond, T. A. Dawson, L. Wang, K. M. Channon, and D. J. Paterson Gene Transfer of Neuronal Nitric Oxide Synthase into Intracardiac Ganglia Reverses Vagal Impairment in Hypertensive Rats Hypertension, February 1, 2007; 49(2): 380 - 388. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kamendi, O. Dergacheva, X. Wang, Z.-G. Huang, E. Bouairi, C. Gorini, and D. Mendelowitz NO Differentially Regulates Neurotransmission to Premotor Cardiac Vagal Neurons in the Nucleus Ambiguus Hypertension, December 1, 2006; 48(6): 1137 - 1142. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Kojda and R. Hambrecht Molecular mechanisms of vascular adaptations to exercise. Physical activity as an effective antioxidant therapy? Cardiovasc Res, August 1, 2005; 67(2): 187 - 197. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |